ACH-3102 Plus Sovaldi Cures 100% of Genotype 1 in 8 Weeks

November 10, 2014

Eight weeks of ACH-3102 and Sovaldi (sofosbuvir) cured 100 percent of treatment-naive people with genotype 1 of hepatitis C virus (HCV) in a recent study. The Phase II pilot trials included 12 participants who were treated—with Achillion's NS5A inhibitor ACH-3102 and Gilead Sciences' analog polymerase inhibitor Sovaldi—and six additional observational participants who were not. Results were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

Out of the 12 treated participants, 100 percent achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Nine of those participants had a baseline viral load substantially higher than 6 million. None experienced viral breakthrough or post-treatment viral relapse.

To read a press release about the trial, click here.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.hepmag.com/article/ACH-3102-26389-39053746